 |
|
|
| |
Evaluation of the clinical and economic value of sofosbuvir / velpatasvir (SOF / VEL) in patients with chronic hepatitis C in Spain during the last 5 years
|
| |
| |
EASL 2022 June 22-26 London
Rafael Esteban1, Raquel Domínguez-Hernández2, Helena Cantero3, Miguel Ángel Casado2
Hospital Vall' d'Hebrón, Barcelona, España; 2Pharmacoeconomics & Outcomes Research Iberia (PORIB), Madrid, España; 3Gilead Sciences, España
|
| |
|
|
|
|
|
